title: [Chronic myeloid leukemia].
authors.affiliation: Abteilung Hämatologie undinternistische Onkologie, und Universitäts TumorCentrum am Universitätsklinikum Jena. andreas.hochhaus@med.uni-jena.de
authors.forename: A
authors.initials: A
authors.lastname: Hochhaus
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides; D004252:DNA Mutational Analysis; D004305:Dose-Response Relationship, Drug; D016313:Genes, abl / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D018365:Neoplasm, Residual / Q000188:drug therapy; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases